Cost utility analysis of deferasiroxversus deferoxamine for patients requiring iron chelation therapy in the United Kingdom

被引：0
作者：
Karnon, J.
Akehurst, R. L.
Jewitt, K.
Ossa, D.
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Novartis Plc, Camberley, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0598
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [21] Subcutaneous iron chelation therapy, oral iron chelation therapy, or both in patients with thalassemia?
    Babrs, Gihan M.
    Abd El-Hakeem, Mohammed A.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2013, 38 (02) : 51 - 55
  • [22] A COST-UTILITY ANALYSIS OF LIGHTERLIFE TOTAL AS A TREATMENT FOR OBESITY IN THE UNITED KINGDOM
    Lewis, L.
    Taylor, M.
    VALUE IN HEALTH, 2013, 16 (07) : A385 - A385
  • [23] IRON CHELATION-THERAPY WITH DEFEROXAMINE FOR TRANSFUSION-DEPENDENT REFRACTORY-ANEMIA
    FRAME, JN
    CHIKKAPPA, G
    BLOOD, 1994, 84 (10) : A547 - A547
  • [24] Safety and Efficacy of Combined Chelation Therapy with Deferasirox and Deferoxamine in a Gerbil Model of Iron Overload
    Otto-Duessel, Maya
    Brewer, Casey
    Gonzalez, Ignacio
    Nick, Hanspeter
    Wood, John C.
    ACTA HAEMATOLOGICA, 2008, 120 (02) : 123 - 128
  • [25] Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox
    Economou, Marina
    Printza, Nikoletta
    Teli, Aikaterini
    Tzimouli, Vassiliki
    Tsatra, Ioanna
    Papachristou, Fotis
    Athanassiou-Metaxa, Miranda
    ACTA HAEMATOLOGICA, 2010, 123 (03) : 148 - 152
  • [26] LONG-TERM EFFICACY OF DEFEROXAMINE IRON CHELATION-THERAPY IN ADULTS WITH ACQUIRED TRANSFUSIONAL IRON OVERLOAD
    SCHAFER, AI
    RABINOWE, S
    LEBOFF, MS
    BRIDGES, K
    CHERON, RG
    DLUHY, R
    ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (07) : 1217 - 1221
  • [27] Evaluation of the cost-utility of orlistat (Xenical) in the United Kingdom
    McEwan, P
    Jones, M
    Farina, C
    Currie, CJ
    VALUE IN HEALTH, 2004, 7 (06) : 721 - 721
  • [28] Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major
    Zargari, Ahmad
    Wu, Simon
    Greenway, Anthea
    Cheng, Ken
    Kaplan, Zane
    VOX SANGUINIS, 2022, 117 (05) : 733 - 737
  • [29] COMBINED CHELATION THERAPY WITH DEFERASIROX AND DEFEROXAMINE IN TRANSFUSION-DEPENDENT PATIENTS WITH THALASSEMIA
    Ladis, V.
    Delaporta, P.
    Kyriakopoulou, D.
    Kattamis, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 703 - 703
  • [30] A novel approach to iron chelation therapy: Twice-daily subcutaneous injections of deferoxamine in the treatment of transfusional iron overload in pediatric patients.
    Medini, I
    McDonough, EA
    Nelson, SC
    BLOOD, 1998, 92 (10) : 31B - 31B
12345